Strategies and prospects for vaccination against the hepatitis C viruses

Current Topics in Microbiology and Immunology

Volumn 242, Issue , 2000, Pages 327-339

  Houghton, M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VACCINE; NUCLEIC ACID; RECOMBINANT VACCINE; VIRUS PROTEIN;

DRUG RESEARCH; HEPATITIS C VIRUS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

HEPATITIS C VIRUS;

EID: 0033992517     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-59605-6_15     Document Type: Review

References (5)

1. Adams G, Kuntz S, Rabalais G, Bratcher D, Tamburro CH et al. (1997) Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children. Pediatr Infect Dis J 16:533-534
2. Allander T, Beyene A, Jacobson SH, Grillner L, Persson MAA (1997) Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-spccific antibody response. J Infect Dis 175:26-31
3. Alter HJ (1989) Chronic consequences of non-A, non-B hepatitis. In: Seef LB, Lewis JH (eds) Current prospective in hepatology. Plenum, New York, pp 83-97
4. Alter MJ (1993) The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 2:155-166
5. Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A et al. (1995) Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 69:2462-2470